【环球网财经综合报道】日前，国家医保局、人力资源社会保障部印发《国家基本医疗保险、生育保险和工伤保险药 品目录》以及《商业健康保险创新药品目录》，自2026年1月1日起正式执行。这是国家医保局成立以来第8次调整医 保药品目录。本次医保药品目录调整新增114种药品，其中50种为1类创新药。 值得关注的是，本次调整后，多款罕见病药物被纳入2025年医保目录及商保创新药目录。其中复星医药的芦沃美替尼 片进入2025年医保目录，北海康成的注射用维拉苷酶β进入商保创新药目录。同时，5款CAR-T药进入商保创新药目 录，分别是复星凯瑞的阿基仑赛注射液、药明巨诺的瑞基奥仑赛注射液、合源生物的纳基奥仑赛注射液、驯鹿生物的 伊基奥仑赛注射液、科济药业的泽沃基奥仑赛注射液。 国家医疗保障局党组书记、局长章轲还表示，将加快基于医保数据、医保立项和支付的场景，加快医保影像云建设， 力争2027年以前基本实现医保影像的全国互通互认。 《南华早报》近日发文称，花旗银行亚太区医疗保健研究总监约翰·杨表示，"未来几年，生物科技，尤其是创新药 物，肯定会是中国的头等大事。"他认为，中国需要通过升级生产线和生产能力，以及扩大临床管理能力，来发展 ...

药明巨诺建有三个经国家药监局批准的CAR-T生产模块，其中模块三为国内唯一获批传染病阳性患者 CAR-T生产车间，保障了产品的可及性与安全性。 2025年10月，倍诺达®新增使用国产病毒载体的上市后补充申请获药监局正式受理，标志着核心物料自 主可控，预计慢病毒载体的物料成本将显著下降。其自建的高规格慢病毒载体生产车间采用悬浮生产工 艺，突破传统贴壁工艺的限制。相较于后者单批次仅能供应约100人份的产能，药明巨诺的单批次产量 可提升至1500人份CAR-T治疗需求，显著提高了生产效率和供应能力。 2025年4月，药明巨诺将其自研的慢病毒载体生产工艺授权予美国Juno公司，实现中国细胞治疗技术的 反向出口，展现出中国创新的国际竞争力。 04 多管线研发并行，全球化布局加速 政策引领与产业创新双轮驱动，助力"健康中国2030" 2025年12月7日，国家医保局正式发布《商业健康保险创新药品目录》。药明巨诺（2126.HK）的倍诺 达®（瑞基奥仑赛注射液）凭借突出的临床价值与创新性，成功纳入首批创新药目录。这标志着中国创 新药可及性改革迈出关键一步，细胞免疫治疗正式进入"商保+创新药"协同新阶段，为更多中国患者使 用 ...

（文章来源：北京商报） 具体来看，包括复星凯瑞的阿基仑赛注射液、药明巨诺的瑞基奥仑赛注射液、驯鹿生物的伊基奥仑赛注 射液、合源生物的纳基奥仑赛注射液、以及恺兴生命科技的泽沃基奥仑赛注射液。 北京商报讯12月7日，《商业健康保险创新药品目录（2025年）》正式发布，18家创新药企业的19款药 品成功纳入，其中包括五款CAR-T产品。 ...

Core Insights - The introduction of five CAR-T cell therapies into the Commercial Health Insurance Innovative Drug Directory marks a significant breakthrough for these high-cost treatments, which previously struggled to gain access to national insurance negotiations [1][3][4] Group 1: Benefits of Inclusion - The five CAR-T therapies included are aimed at treating various blood cancers, providing hope for potential cures in conditions like large B-cell lymphoma, multiple myeloma, and acute lymphoblastic leukemia [3] - The inclusion of these therapies in the directory is seen as a milestone for improving patient accessibility to innovative drugs in China [4][5] - The pricing of these therapies varies, with the lowest being 999,000 yuan (approximately 99.9 million) for the product from 合源生物, while the highest is 1,290,000 yuan (approximately 129 million) for the product from 药明巨诺 [1] Group 2: Market Dynamics and Cost Considerations - The high production costs of CAR-T therapies, particularly due to the expensive lentiviral vectors sourced from foreign suppliers, have historically limited their pricing and accessibility [3] - Some companies have reported that their CAR-T products will see price reductions of at least 15% upon inclusion in the directory, which is expected to be more favorable than local health insurance programs [5] Group 3: Implementation Challenges - The successful inclusion of CAR-T therapies in the directory raises questions about the practical implementation and accessibility in hospitals, as the directory's effectiveness relies on its adoption at the hospital level [6][7] - Policies such as the "three exclusions" from basic medical insurance and centralized procurement monitoring are designed to alleviate concerns from hospitals and physicians regarding cost assessments, potentially facilitating the entry of these drugs into hospitals [6][7] - There are ongoing discussions about further coordination between the National Medical Insurance Administration and health authorities to ensure that the performance assessments of hospitals do not hinder the adoption of these innovative therapies [7]

Core Viewpoint - The launch of the China Drug Price Registration System marks a significant step towards a globalized pricing framework for innovative drugs, enhancing market-oriented pricing capabilities for pharmaceutical companies and supporting the development of a new pricing ecosystem that aligns drug prices with innovation value and market demand [1][2][6]. Group 1: Drug Price Registration System - The new system allows domestic and international pharmaceutical companies to independently register drug prices, ensuring accountability for price authenticity [1][3]. - The system operates under the principle of "one location acceptance, nationwide sharing, global openness," and is managed by a state-owned enterprise in Beijing [1][3]. - The first batch of companies to register prices includes major players such as China National Pharmaceutical Group, Beijing Tongrentang, and Roche, indicating strong industry participation [3]. Group 2: Impact on Pharmaceutical Industry - The system is expected to enhance the pricing strategies of pharmaceutical companies, allowing them to adjust prices based on clinical value, supply-demand dynamics, and competitive landscape [3][4]. - The dual mechanism of registration and query will promote transparency in drug pricing, moving away from previous opaque practices [4]. - The establishment of this system is anticipated to create a comprehensive pricing structure that encompasses innovative drugs, insurance payment prices, and generic drug prices, benefiting the innovative drug sector [5]. Group 3: Global Market Development - The China Drug Price Registration System is designed to facilitate the international expansion of Chinese innovative drugs and attract high-quality foreign drugs into the Chinese market [2][5]. - Data indicates that the total amount of overseas licensing transactions by Chinese pharmaceutical companies exceeded $92 billion in the first three quarters of 2025, highlighting the growing global presence of Chinese innovative drugs [2]. - The system aims to address significant price discrepancies between domestic and international markets, influenced by factors such as currency exchange rates and pricing mechanisms [5]. Group 4: Long-term Industry Implications - The implementation of the drug price registration system is expected to enhance the global competitiveness of China's biopharmaceutical industry and drive high-quality innovation within the sector [6].

Core Insights - The launch of the Chinese Drug Price Registration System on December 2 is seen as a significant positive development for the innovative drug sector, facilitating the international expansion of domestic innovative drugs [1][4]. Group 1: Drug Price Registration System - The Chinese Drug Price Registration System was launched on December 2, with nine pharmaceutical companies participating in the initial registration, including both multinational and traditional Chinese medicine firms [2]. - The system currently includes limited information, with only 10 drug entries available, indicating a nascent stage of development [2]. - The system allows for independent pricing by companies outside of the National Medical Insurance (NMI) framework, which is a notable shift in policy [1][5]. Group 2: Innovative Drugs Highlighted - Four drugs showcased on the system are recognized as either the first of their kind in China or globally, including innovative treatments like Toripalimab and Icaritin [3]. - For instance, Toripalimab is the first Chinese PD-1 monoclonal antibody approved in both Europe and the U.S., while Icaritin is the first CAR-T therapy targeting BCMA approved in China [3]. Group 3: Market Implications - The establishment of the registration system is expected to enhance the global pricing framework for Chinese innovative drugs and attract high-quality foreign drugs to the Chinese market [4][5]. - Data indicates that in the first three quarters of 2025, Chinese pharmaceutical companies completed 103 license-out transactions totaling $92.03 billion, highlighting the growing importance of the Chinese market in the global pharmaceutical industry [4]. - The NMI's non-interference in pricing for the non-NMI market is seen as a positive step towards respecting market dynamics and enhancing the pricing power of domestic companies in international markets [5].

Core Insights - The launch of the Chinese Drug Price Registration System on December 2 is seen as a significant positive development for the innovative drug sector, facilitating the international expansion of domestic innovative drugs [1][4] - The system allows for independent pricing by companies outside of the National Medical Insurance (NMI) market, which is expected to foster a more competitive environment [1][5] Group 1: Drug Price Registration System - The Chinese Drug Price Registration System was launched on December 2, with nine pharmaceutical companies participating in the initial registration, including both multinational and domestic firms [2] - The system currently includes limited data, with only 10 drug entries available, indicating a nascent stage of development [2] - The system is designed to respect the pricing autonomy of companies in the non-NMI market, which is a shift from previous perceptions that equated the NMI market with the entire Chinese pharmaceutical market [5] Group 2: Innovative Drugs Highlighted - Four drugs showcased on the system's homepage hold either domestic or global "first" status, including innovative treatments like the first Chinese PD-1 monoclonal antibody approved in Europe and the U.S. [3] - Specific pricing examples illustrate the disparity between NMI reimbursement prices and companies' self-reported prices, such as the self-reported price of 10,688 yuan for a PD-1 monoclonal antibody compared to the NMI price of 1,253.53 yuan [3] Group 3: Market Implications - The establishment of the drug price registration system is expected to enhance the global pricing framework for Chinese innovative drugs and attract high-quality foreign drugs to the Chinese market [4] - Data indicates that Chinese pharmaceutical companies completed 103 license-out transactions worth 9.203 billion USD in the first three quarters of 2025, highlighting the growing importance of the Chinese market in the global pharmaceutical industry [4] - The NMI's non-interference in pricing for the non-NMI market is viewed as a positive step towards empowering companies to set prices that reflect market conditions, potentially increasing their influence in international markets [5]

FF301 致：香港交易及結算所有限公司 公司名稱: JW (Cayman) Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司* 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02126 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券 ...

Core Viewpoint - The Hong Kong pharmaceutical stocks experienced a significant downturn, with notable declines in several companies' stock prices [1] Group 1: Company Performance - Gilead Sciences (歌礼制药-B) saw a drop of over 8% in its stock price [1] - Sanofi (圣诺医药-B) experienced a decline of more than 6% [1] - Deciphera Pharmaceuticals (德琪医药-B) fell by over 4% [1] - Other companies such as Innovent Biologics (复宏汉霖) and Antengene Corporation (药捷安康-B) also followed the downward trend [1]

Core Viewpoint - The launch of the drug price registration system in China is a significant step towards establishing a global pricing framework for innovative drugs, enhancing the international competitiveness of Chinese pharmaceutical companies [1][3][6]. Group 1: Drug Price Registration System - The drug price registration system, initiated by the National Healthcare Security Administration, allows domestic and foreign pharmaceutical companies to independently declare drug prices, creating a comprehensive pricing archive [1][3]. - The system operates independently from provincial procurement platforms and follows principles of "one location acceptance, nationwide sharing, and global openness," which aids in building a globalized drug pricing system [1][3]. - The registration of prices does not alter the medication costs for insured and uninsured individuals [1]. Group 2: Support for Chinese Pharmaceutical Companies - The new system addresses the shortcomings in the pricing mechanism for innovative drugs, facilitating their entry into international markets and allowing for pricing that aligns with local payment systems [3][4]. - Companies like Yifan Pharmaceutical highlight that the system will provide substantial support for overseas expansion, allowing for a more accurate reflection of the true value of innovative drugs [4]. - The system enables companies to register prices according to international practices, providing verifiable pricing information to regulatory bodies and partners [4]. Group 3: Attracting Foreign Innovative Drugs - The establishment of the drug price registration system is expected to attract more high-quality foreign innovative drugs into the Chinese market, as multinational companies will be encouraged to participate in national healthcare negotiations [6][7]. - The system allows multinational companies to register prices independently in China, creating a clear distinction between market supply prices and negotiated healthcare prices, which enhances the certainty of market entry for innovative drugs [7].